A digital-generated image of Samsung Biologics' Plant 5 in Songdo, Incheon. [SAMSUNG BIOLOGICS] Pharma manufacturer Samsung Biologics has secured $897 million worth of deals from Pfizer Ireland Pharmaceuticals, the Incheon-based company said Tuesday. The deals, which followed a letter of intent signed with Pfizer in June, are a $704-million contract manufacturing organization (CMO) deal and an additional $193 million order from a previous contract worth $183 million clinched on March 2. With the addition of the latest contracts, Samsung Biologics' contract value from Pfizer this year totals $1.

https://n.news.naver.com/mnews/article/640/0000040338?sid=101

#naver